Real-world patterns of first-line treatment selection after the introduction of enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma
Authors:
Open Access
- 25 August 2026
- journal article
- research article
- Published by Springer Nature in BMC Cancer
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Japan Society for the Promotion of Science (25K02769)